Xarelto (rivaroxaban) is one of the newest anticoagulants – more commonly known as blood thinners. The drug is an oral medication developed by Bayer and Johnson & Johnson’s Janssen Pharmaceuticals.  Blood thinners prevent dangerous blood clots that can obstruct the blood flow to the vital organs. Unlike older anticoagulants that require doctors to prescribe specific doses for each individual, Xarelto belongs to a new type of oral anticoagulant that is prescribed in one uniform dose.

xarelto-screen-shot

The Food and Drug Administration (FDA) approved Xarelto for use in patients who have had knee or hip replacement surgery to reduce the risk of blood clots, reducing the risk of stroke in people with AF. Following a fast-track regulatory review, the FDA approved the drug for general treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).

One of the most severe side effects of Xarelto is uncontrolled bleeding.  When bleeding occurs near a major organ, such as the brain, lungs or kidneys, blood flow to that organ is interrupted, causing it to lose some or all of its functionality. Also, pools of blood may form within the body and can cause other severe health risks. Because Xarelto prevents clotting, the hemorrhaging will continue until the drug is flushed out of the system.

At least two thousand product liability lawsuits have been filed against Bayer and Janssen.  In December 2014, the U.S. Judicial Panel on Multidistrict Litigation established consolidated proceedings for all Xarelto injury cases, transferring all complaints filed throughout the federal court system to U.S. District Judge Eldon Fallon in the Eastern District of Louisiana.  As part of the coordinated pretrial proceedings, Judge Fallon has indicated that a small group of representative cases in the litigation will be prepared for early trial dates to help gauge how juries are likely to respond to certain evidence and testimony that is likely to be repeated throughout a number of other cases.  The first Xarelto trial dates are not expected to begin until August 2016.

If you have experienced complications as a result of your Xarelto, please call Cowper Law at 877.LAW.3707 to speak with an attorney about your rights. We are attorneys with experience in medical device and pharmaceutical litigation. Let us help fight for you.